Current Research Trials Looking For Participants:
Dr. Heather Reich is leading this project to create a network to develop personalized treatments for patients with Glomerulonephritis (GN) and identify new ways of detecting high-risk GN. To do this, the research team will build upon an established research program to develop a collaborative national patient-centred program. They will expand a successful clinical database structure, so it is available to the Canadian research community. The research team will study strategies for GN treatment that are tailored to a patient’s individual needs and will look for specific genes and proteins that can help predict disease progression and whether an individual will benefit from innovative treatments. Patients enrolled in our study will be seen every six months for blood tests and updates regarding their health and well-being.
Advanced chronic kidney disease requiring dialysis is expensive and is associated with poor health outcomes and quality of life. To report symptom burden and quality of life adjusted-survival alongside clinical and laboratory measures, it is imperative to measure and report what is important to patients. Patient-reported outcome measures (PROMs) could be used to capture patients’ experiences of symptoms and impact of disease on functioning, and can support clinicians to monitor disease progression and facilitate patient-centered care.
This trial, lead by Drs Jeffrey Johnson and Michael Walsh, aims fill these gaps by evaluating the impact of routinely measuring and reporting to care providers of PROMs on patient-reported experience and outcomes, clinical outcomes, and healthcare utilization.
Canada's rate of living kidney donation has stagnated since 2006 and is 35% lower than several Western nations.
This project, led by Dr. Amit Garg, will develop solutions to help overcome barriers to living kidney donor transplantation. Two priority areas, chosen by patient partners, are to improve the quality and efficiency of the donor candidate evaluation process throughout Canada and to evaluate provincial solutions to support patients with kidney failure in their pursuit of living kidney donation. These solutions include administrative support to programs and providers, a patient-centred approach to transplant education and choice, and peer mentorship. Check out their website – www.transplantambassadors.ca.
Interested in Seeing More Research Trials?
Visit ClinicalTrials.gov's DatabaseView More
Advances in autosomal dominant polycystic kidney disease (ADPKD) research have identified a number of promising therapeutic drugs and several of these drugs are re-purposed compounds that are currently approved for other diseases.
This study, led by Dr. York Pei, will perform two pilot trials to test the efficacy and safety of these therapeutic drugs for treating ADPKD. Patient and family input will be included in the design and execution of these studies. Check out their website - https://www.cimpkd.ca/research.html
Indigenous people have a higher risk of chronic kidney disease (CKD) and kidney failure compared to the non-Indigenous population and many Indigenous people live in rural communities where there is limited access to doctors and appropriate health care services.
This team, led by Dr. Paul Komenda, will conduct a screening initiative in Indigenous communities in five provinces across Canada. Using mobile lab equipment, screening teams will travel to communities and test for CKD and its risk factors, including diabetes and high blood pressure. This information will be used to determine an individual’s risk of CKD, and each person will receive a treatment plan that is tailored to their risk. This may include counseling, treatment recommendations, an appointment with a doctor, or direct referral to a kidney specialist. Check out their website – www.kidneycheck.ca.
Young people diagnosed with type 1 diabetes are at risk of long-term complications, including kidney and heart disease. Led by Drs. James Scholey, Farid Mahmud and Etienne Sochett, the AdDIT project is studying an observational cohort of youth with type 1 diabetes along with a group of healthy age-matched subjects and assessing both kidney function and cardiovascular function over time. This project is joining with iCARE (Improving Renal Complications in Adolescents with Type 2 Diabetes through Research) to lead to a better understanding of why kidney injury happens in youth with diabetes, and what can potentially be done to stop or slow down this process in order to decrease the risk of kidney failure in adulthood. Check out their website at www.addit-trial.org.
Kidney disease is common, but not all patients will reach kidney failure. In most patients, risk factors can be controlled and kidney function can stay stable for many years. Yet, most patients live in fear of kidney failure. In 2011, Dr. Navdeep Tangri and his team, developed an equation that accurately predicts the risk of kidney failure in patients with kidney disease. The equation uses routine lab tests, and can help patients and their doctors understand their risk better. This information reduces anxiety and empowers patients to better control their disease and its risk factors.
The equation will be tested via interactive tools in family medicine clinics across Canada. The interactive tools will help patients and their doctors gain a better understanding of their kidney health and will help guide their care. Check out their website – www.kidneyfailurerisk.com.
Drs. Allison Dart and Brandy Wicklow lead this research team who are working together with the AdDIT team (Adolescent Diabetes Cardio-Renal Intervention Trial) to identify the most important risk factors for early kidney disease in youth with diabetes. There are important differences in the timing of onset and rates of progression of chronic kidney disease (CKD) in youth with type 1 and type 2 diabetes.
The study is measuring biological, psychological and social factors in youth, as well as a panel of biomarkers (markers of inflammation, proteins, hormones and kidney filter micro-particles) in order to broadly address our project goal. Check out their website - https://www.dreamdiabetesresearch.com/icare
Drs. Michael Walsh and David Collister are leading this large international study with over 2750 patients receiving dialysis to determine if spironolactone reduces heart related deaths and hospitalizations due to heart failure. Patients will be randomly assigned to spironolactone or a placebo pill that looks and tastes just like spironolactone but does not have any spironolactone in it. Patients will be followed for about five years in order to determine how often heart problems occurs in patients who take spironolactone compared to those that take the placebo. Another objective of the study is to determine whether the spironolactone changes patient’s quality of life or the degree to which they feel unwell or washed out after dialysis.